OFFER DEADLINE30/06/2020 00:00 - Europe/Brussels
EU RESEARCH FRAMEWORK PROGRAMMEH2020 / Marie Skłodowska-Curie Actions
The Heart Failure, Ischemic Cardiopathy and Valvulopathy research group at the Biomedical Research Institute of Málaga - IBIMA (Málaga, Spain) is interested in hosting a Marie Curie Fellowship. Two Marie Skłodowska-Curie projects are offered to be supervised by Dr. Francisco Javier Pavón. The hosting group belongs to the Cardiology and Cardiac Surgery Unit at Hospital Universitario Virgen de la Victoria and is part of the Cardiovascular Diseases Networking Biomedical Research Center - CIBERCV (funded by the National Health Agency) from 2008. Dr. Jiménez Navarro is the coordinator of the research group, which develops clinical and preclinical studies from a translational perspective with a multidisciplinary staff that combines scientific, academic and clinical activities. Dr. Pavón has been working in numerous basic and clinical studies focused on the characterization of inflammatory signaling systems (e.g., cytokines, chemokines, growth factors and fatty acid-derived mediators such as endocannabinoids) associated with obesity, addiction and common comorbidities, mainly psychopathologies and cardiovascular diseases. The main objective of these studies has been the identification of potential biomarkers and the development of pharmacological tools to improve the prognosis, diagnosis and/or treatment of the patients. Dr. Pavón is currently management committee member from Spain of the COST action CA15135 –MuTaLig. In addition, he participates as researcher in the Spanish Network for Addictive Disorders from 2010. His wide scientific career is supported by more than 100 peer-reviewed articles (indexed in Pubmed), 5 patents with PCT extension, 5 projects as PI and more than 30 projects as collaborator (2 European projects: REPROBESITY - HEALTH-F2-2008-223713 and FATZHEIMER - EULACH16/T01-0131) and supervision of 4 PhD students.
Description of the center:
The IBIMA is a space for multidisciplinary biomedical research that gather the resources, skills and expertise of the main public University Hospitals, Primary Care Centers and the University of Málaga to constitute a strong collaborative structure (www.ibima.eu/en). The institute promotes translational research in order to accelerate the transference of the scientific breakthroughs into the health care system through the improvement of the prevention, diagnosis and treatment. The IBIMA has been accredited as a Health Research Institute since January 15th, 2015 by the Carlos III Health Institute (National Health Agency), on the basis of the Spanish Royal Decree 339/2004 of February 27th. It has a workforce of about 900 people, with more than 700 researchers, 114 technicians and 34 managers, clustered in 44 consolidated groups, 4 emergent groups and 7 associated groups. The IBIMA performs research activities within the scope of the Andalusian Health System - SAS (Servicio Andaluz de Salud), which belongs to the Ministry of Health and Families of the Government of Andalusia (Junta de Andalucía), in the South of Spain. Its mission is to provide a high-quality healthcare system to the citizens of Andalusia seeking efficiency and optimization of the use of public resources. At Málaga province, the SAS provides care to a population of 1,600,000 habitants coordinating the services of 2 university hospitals (Hospital Regional Universitario de Málaga and Hospital Universitario Virgen de la Victoria) and 48 primary care centers in the city of Málaga together with those services located throughout the rural area of the province (4 hospitals and 107 primary care centers).
The IBIMA Strategic Plan 2018-2022 defines the evolution of the Institute taking into account the European, national and regional research policies, welcoming the collaboration with private entities and analyzing the province health indicators to establish the course of actions to become a scientific and technological reference for Málaga and the international community. The backbone of the IBIMA organization has been the prioritization of the lines of research pursuing the greatest impact on the health of the citizens. The institute is structured around 4 priority and 2 transversal research areas, where the research groups, the common research facilities (Estructuras comunes de apoyo a la investigación, ECAI) and the research support units (Unidades de apoyo a la Investigación, UAI) are coordinated for the execution and the management of the research.
1 Cardiovascular diseases, obesity and diabetes. Environmental determinants and lifestyle
2 Oncology and hematology
3 Neurosciences, chronicity, aging and health in vulnerable populations
4. Autoimmune, infectious diseases, inflammation and allergy
5. Transversal 1. IBIMA Rare: Rare diseases
6. Transversal 2. IBIMA Tech: Technology area in health and Innovation
1. Clinical studies 6. Microscopy
2. Biobank 7. Cellular biology (cytometry and cultures)
3. Bioinformatics 8. Cell production and GMP rooms
4. Animal research 9. Proteomics
5. Genomics 10. Methodological and statistical advice
1. Quality, monitoring and evaluation
2. Project management
3. International projects
4. Innovation and technology transfer
In addition, the IBIMA Training Plan 2018 - 2022 defines the aims and objectives regarding the training of staff providing seminars, courses and events designed to promote and assure high-quality scientific and technical knowledge. Furthermore, the IBIMA collaborates with the University of Málaga through post-grade doctoral programs and masters in life science and health.
The integral management and promotion of research & development and innovation for the IBIMA are provided by the Andalusian Public Foundation for Health and Biomedicine Research in Málaga – FIMABIS. The FIMABIS is a non-profit foundation that is independent of the governing structures of the IBIMA partners, which allows an efficient economic and administrative management that complies with the regional, national and international governmental-public and private funding agencies normative.
In July 2017, the European Commission awarded IBIMA - FIMABIS the HRS4R Seal in recognition of the commitment acquired in implementing the principles of the "European Charter of Researcher and Code of Conduct in the Recruitment of Researchers " through its HRS4R strategy Implementation Plan.
Description of the group:
The Heart Failure and Ischemic Cardiopathy group of the Cardiology and Cardiac Surgery Unit at the Hospital Universitario Virgen de la Victoria belongs to the IBIMA research area 1 (Cardiovascular diseases, obesity and diabetes. Environmental determinants and lifestyle). The group is led by Dr. Jiménez-Navarro, cardiologist and professor at University of Málaga with a strong experience in the integration of basic and clinical research and the implementation of translational approaches in the unit. This is a multidisciplinary group that includes postdoctoral and predoctoral researchers (cardiologists, biologists, psychologists...), nurses and lab technicians. There are 3 main research lines:
1. Clinical efficiency of new percutaneous treatments for structural heart diseases
2. Strategies for the prevention, diagnosis and treatment of coronary heart disease
3. Cardiovascular translational research: genetics and cardiovascular disease
Regarding the participation in collaborative scientific structures, the hosting group is part of the Cardiovascular Diseases Networking Biomedical Research Center - CIBERCV from 2008 and the Network of Addictive Disorders - RTA from 2010. Both CIBERCV and RTA are funded by the National Health Agency.
Description of the project/projects:
The project proposals are as follows:
Description Principal Investigator (education, research experience, publications, projects, ORCID ID, Researcher ID or other, etc.)
Dr. Pavón obtained his Bachelor of Science (Biology) and completed his PhD at the University of Málaga (Málaga, Spain) in 2006 working in the effects of endocannabinoids and analog lipid compounds on obesity and addictive disorders. He moved to The United States of America in 2007, where he worked as a postdoctoral fellow in the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute (La Jolla, CA). Dr. Pavón returned to Spain in 2010 and joined the Network of Addictive Disorders as researcher at the IBIMA. In 2015 he reached an PI position and developed new lines of research on the characterization of chemokine signaling systems in the context of addictions and their comorbidities, including psychopathologies and cardiovascular complications. Currently, he is a senior PI who performs translational research in the Cardiology and Cardiac Surgery Unit through the Monardes Program (Andalusian Health System, SAS). Dr. Pavón is interested in the characterization of inflammatory signaling systems associated with obesity and addiction as risk factors for cardiovascular diseases. The main objective of these studies is the identification of biomarkers and therapeutic targets considering the influence of aging and sex differences in the expression of inflammatory factors.
A summary of the scientific production: 100 original articles, 8 review articles, 2 book chapters, participation in 38 competitive projects and 5 patents (PCT extensions) and supervision of 4 PhD students and 1 clinical researcher (Río Hortega Program).
ORCID Id: 0000-0002-5256-8904
Researcher ID: AAG-9721-2020
Publications= 105 articles (2015-2020= 76 articles)
See Pavon FJ OR Pavon-Moron OR Javier Pavon in PUBMED
• Montesinos J et al. Neuropharmacology. Vol. 162, 107840. (2020). doi: 10.1016/j.neuropharm.2019.107840. 4.367 Impact Factor 2018 JCR: Science, Q1
• Araos P et al. Scientific Reports. Vol. 9(1): 16842 (2019). doi: 10.1038/s41598-019-53312-0. 4.011 Impact Factor 2018 JCR: Science, Q1
• Pavón FJ et al. Addiction Biology. Vol. 24(6), 1204-15 (2019). doi: 10.1111/adb.12695. 4.223 Impact Factor 2018 JCR: Science, D1-Q1
• Sampedro-Piquero P et al. Neuroscience & Biobehavioral Reviews. Vol. 106, 23-48 (2019). doi: 10.1016/j.neubiorev.2018.11.015. 8.002 Impact Factor 2018 JCR: Science, D1-Q1
• Rivera P et al. Pediatric Obesity. Vol. 14(3), e12473 (2019). doi: 10.1111/ijpo.12473. 3.713 Impact Factor 2018 JCR: Science, D1-Q1
• Moreno M et al. Addiction Biology. Vol. 23(6), 1251-61 (2018). doi: 10.1111/adb.12694. 4.223 Impact Factor 2018 JCR: Science, D1-Q1
• Coin Araguez L et al. Scientific Reports. Vol. 8(1):17518 (2018). doi: 10.1038/s41598-018-35759-9. 4.011 Impact Factor 2018 JCR: Science, Q1
• Serrano A et al. Neuropsychopharmacology. Vol. 43(9), 1840-50 (2018). doi: 10.1038/s41386-018-0055-3. 7.160 Impact Factor 2018 JCR: Science, D1-Q1
• Pavon FJ et al. Addiction Biology. Vol. 23(2), 723-34 (2018). doi: 10.1111/adb.12531. 4.223 Impact Factor 2018 JCR: Science, D1-Q1
• Gutiérrez Sacristán A et al. Database: The Journal of Biological Databases and Curation. bax043 (2017). doi: 10.1093/database/bax043. 3.978 Impact Factor 2017 JCR: Science, D1-Q1
• Garcia-Marchena N et al. Addiction Biology. Vol. 22(5), 1366-77 (2017). doi: 10.1111/adb.12408. 5.578 Impact Factor 2017 JCR: Science, D1-Q1
• Castilla-Ortega E et al. Neuroscience & Biobehavioral Reviews. Vol. 66, 15-32 (2016). doi: 10.1016/j.neubiorev.2016.03.030. 8.299 Impact Factor 2016 JCR: Science, D1-Q1
• Castilla-Ortega E and Pavón FJ et al. Neuropharmacology. Vol. 103, 92-103 (2016). doi: 10.1016/j.neuropharm.2015.12.010. 5.012 Impact Factor 2016 JCR: Science, D1-Q1
• Decara J and Pavón FJ E et al. Disease Models & Mechanisms. Vol. 8(10), 1213-25 (2015). doi: 10.1242/dmm.019919. 4.316 Impact Factor 2015 JCR: Science, Q1
• Wulff-Pérez and Pavón FJ et al. Nanomedicine UK. Vol. 9(18), 2761-72 (2014). doi: 10.2217/nnm.14.35. 5.413 Impact Factor 2014 JCR: Science, D1-Q1
• Pavon FJ et al. Addiction Biology. Vol. 18(6), 955-69 (2013). doi: 10.1111/adb.12107. 5.929 Impact Factor 2013 JCR: Science, D1-Q1
• Serrano A and Pavón FJ et al. American Journal of Physiology-Endocrinology and Metabolism. Vol. 302(7), E817-30 (2012). doi: 10.1152/ajpendo.00468.2011. 4.514 Impact Factor 2012 JCR: Science, Q1
• Alonso et al. British Journal of Pharmacology. Vol. 165(7), 2274-91 (2012). eCollection 2012. doi: 10.1111/j.1476-5381.2011.01698.x. 5.067 Impact Factor 2012 JCR: Science, D1-Q1
• Ramchandani VA et al. Molecular Psychiatry. Vol. 16(8), 809-17 (2011). doi: 10.1038/mp.2010.56. 13.668 Impact Factor 2011 JCR: Science, D1-Q1
• Long et al. Nature Chemical Biology. Vol. 5(1), 37-44 (2009). doi: 10.1038/nchembio.129. 16.058 Impact Factor 2009 JCR: Science, D1-Q1
• Cano C and Pavón FJ et al. Journal of Medicinal Chemistry. Vol. 50(2), 389-93 (2007). doi: 10.1021/jm0601102. 4.895 Impact Factor 2007 JCR: Science, D1-Q1
H Index= 23; Citations= 2,250
Patents= 5 with PCT extensions
Active grants= 5 (total project grants= 38)
Supervisor International collaborations:
1. Title: FATZHEIMER: High Fat Diet, Microbiota and Neuroinflammation in the Progression of Alzheimer Disease. Source and code: EU-LAC Health. (EULACH16/T01-0131). Institutions: Instituto IBIMA-FIMABIS (Spain), German Institute of Human Nutrition (Germany), Ministerio de Ciencia, Tecnología e Innovación Productiva (Argentina), P. Catholic University of Chile (Chile), Universidad de la República (Uruguay), University of Coimbra (Portugal). Duration: 01/01/2018-01/01/2021. Funds: 584.481,00 € Coordinator: Fernando Rodríguez de Fonseca.
2. Title: REPROBESITY: Search for New Therapeutic Agents Against Complicated Obesity By Reprofiling Existing Drugs. Source and code: 7th Framework, EU. (HEALTH-F2-2008-223713). Institutions: IBIMA (Spain), Vivia Biotech S.L. (Spain), INSERM (France), Gutenberg-University Mainz (Germany), Universitat di Bologna (Italy), Universidad de Santiago de Compostela (Spain). Duration: 01/12/2008-30/11/2011. Funds: 598,000 €. Coordinator: Fernando Rodríguez de Fonseca.
1. Management Committee Member for Spain in the COST (European Cooperation in Science and Technology) CA15135-Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig). Participants: 33 COST countries, USA, Brazil. Duration: 2016-2020 extended to 2021. Source: Horizon 2020 Framework Programme (H2020), EU. Funds: 492,136 €. Coordinator: Stefano Alcaro.
In addition to these international consortiums and networks, Dr. Pavón has ongoing collaboration with international research groups such as Dr. Rémi Martin-Fardon and Dr. Marisa Roberto at Scripps Research, La Jolla, USA and Prof. Roberto Ciccocioppo at University of Camerino, Italy.
Supervisor most relevant research projects grants:
Projects as PI
REQUIRED EDUCATION LEVEL
REQUIRED EXPERIENCE LEVEL
Experience in preclinical models (rodents, cultures)
Statistical analysis in biomedicine
Preparation of projects and scientific material
Candidates highly motivated with sense of responsibility, proactivity and capacity for teamwork
At the deadline for the submission of proposals (September 9th, 2020), researchers:
The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.